Time filter

Source Type

Ningxia, China

Ye X.-P.,Ningxia Peoples Hospital | Bao S.,Ningxia Peoples Hospital | Guo L.-Y.,Lanzhou University | Wang X.-H.,Lanzhou University | And 9 more authors.
Translational Oncology | Year: 2013

To evaluate the long-term effect of breast conservation with accelerated partial breast irradiation (APBI) for early-stage breast cancer, PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Literature Database, Chinese Scientific Journals Full-text Database, and China Journal Full-text Database were searched to identify relevant original published trials. Randomized controlled trials in any language comparing APBI with whole-breast radiotherapy in patients with early-stage breast cancerwere included.RevMan 5 softwarewas used for statistical analysis. Four trials involving 919 patients were included. The rate of 5- and 7-year excellent/good cosmetic results was significant {odds ratio (OR) = 2.09 [95% confidence interval (CI) = 1.21-3.62]} between two groups. The 5- and 8-year overall survival had no significant difference [OR = 1.76 (95% CI = 0.67-4.62) and OR = 0.86 (95% CI = 0.44-1.66)]. The 10-year overall survival had significant differences [OR = 0.56 (95% CI = 0.35-0.91)]. There were no differences in the 5-year local recurrence (LR)-free survival [OR = 0.65 (95% CI = 0.18-2.34)], cancer-specific survival [OR = 1.67 (95% CI = 0.39-7.12)], disease-free survival [OR = 0.84 (95% CI = 0.38-1.84)], LR [OR = 1.36 (95% CI = 0.46-3.99)], the rate of contralateral breast cancer [OR = 2.82 (95% CI = 0.73-10.89)], and distant metastasis [OR = 0.71 (95% CI = 0.22- 2.31)]. APBI significantly improved the rate of excellent/good cosmetic results anywhere in the breast, shortened the treatment time, alleviated the pain, and improved the quality of life. Future large-scale, high-quality, and double-blind trials are needed. © 2013 Neoplasia Press, Inc. All rights reserved. Source

Fardmal J.,Hamadan University of Medical Sciences | Mafi M.,Hamadan University of Medical Sciences | Sadighi-Pashaki A.,Radiology Oncology Center | Karami M.,Hamadan University of Medical Sciences | Roshanaei G.H.,Hamadan University of Medical Sciences
Journal of Zanjan University of Medical Sciences and Health Services | Year: 2013

Background and Objective: Breast cancer is the most common cancer among women. Various factors are associated with survival of patients with breast cancer. The aim of this study was to determine the survival rate of patients with breast cancer who referred to MRI center of Hamadan and to explore its related factors. Materials and Methods: In this historical cohort study, 542 women with breast cancer who had referred to Darol-Aitam-e Mahdieh center of Hamadan were included during 2004-2011. All patients had undergone chemotherapy and radiotherapy after surgery. Data were obtained from the patients' medical records and were analyzed using time-dependent Cox model. Results: The mean (SD) age of patients was 46.06 (±10.82) years. The median of survival time was 109.7 months. 201 (37.1%) patients died during the study period. One, five and ten-year survival of the patients was 96.8%, 68% and 31%, respectively. The results of the current study showed that the tumor size and metastasis status were statistically related to the hazard of death in these patients (p<0.05). Conclusion: Age, metastasis status, tumor size, number of involved lymph nodes and the status of progesterone receptor were associated with survival of patients. Since early detection of breast cancer may have an influence on some of these factors, therefore, these results reveals the important role of public education for regular referral to physicians and screening of breast cancer for all women for early detection of breast cancer. Source

Faradmal J.,Hamadan University of Medical Sciences | Roshanaei G.,Hamadan University of Medical Sciences | Mafi M.,Hamadan University of Medical Sciences | Sadighi-Pashaki A.,Radiology Oncology Center | Karami M.,Hamadan University of Medical Sciences
Journal of Research in Health Sciences | Year: 2016

Background: The occurrence and the mortality related to breast cancer (BC) in Iranian female population has increased over time. Although there are many studies on BC and related risk factors, however, the epidemiological aspects of this melanoma in Iranian females are uncertain. Therefore, the aim of this study was to determine the relationship between demographical and clinical factors on the shape of overall survival (OS) distribution in patients with BC. Methods: This historical cohort study was carried out using data from 522 participants with BC. Data were gathered from medical records of these patients admitted to Mahdieh Oncology Center of Hamadan Province, western Iran, from January 2000 to August 2011. Kaplan-Meier estimator was used to estimate the survival rates and, censored quantile regression (CQR) to provide in-depth insight in the multivariable association between prognosis factors and survival rates. Results: Patients' follow-up ranged from around 3 to 197 months. One-, three-, and five-year survival rates were 90%, 73% and 62.5%, respectively. Results of CQR model showed that change in the age at diagnosis, number of involved lymph nodes and tumor size could significantly change the median and some other quantiles of OS. Conclusions: This study, confirm the importance of early detection of BC and usefulness of CQR because of possible changes in distribution family of survival time. © 2016, Health Hamadan University of Medical Sciences. All rights reserved. Source

Liu R.,Lanzhou University | Liu R.,Radiology Oncology Center | Wang X.,Radiology Oncology Center | Ma B.,Lanzhou University | And 3 more authors.
Anti-Cancer Drugs | Year: 2010

The objective of this study was to assess the clinical efficacy and safety of concomitant or adjuvant tomozolomide with whole-brain irradiation (WBI) in patients with brain metastases. MEDLINE, EMBASE, Cochrane Library, Chinese Biomedical Literature Database were searched to identify relevant original published trails, and the references of eligible studies were manually screened. Randomized controlled trails reported in any language, comparing concomitant or adjuvant temozolomide (TMZ) and WBI with WBI alone in patients with brain metastases, were eligible for inclusion. Two investigators independently assessed the quality of included trials and extracted data. The RevMan 5 software was used for statistical analysis. Four trials involving 280 patients were included. The result showed that the group TMZ+WBI was superior to group WBI in partial response, stable disease, progressive disease, and objective response with the pooled risk ratio value and 95% confidence interval, respectively, 1.89 (1.19-3.02), 0.82 (0.45-1.50), 0.29 (0.10-0.78), and 1.72 (1.32-2.24). The incidence of gastrointestinal symptoms and ≥ grade 3 myelosuppression presented statistical difference, TMZ+WBI group is higher than WBI group, the pooled risk ratio value and 95% confidence interval were 3.75 (1.04-13.44) and 13 (1.75-96.79), respectively. The currently available evidence showed that the combination of TMZ and WBI may moderately improve the response rate, but accordingly increase the incidence of gastrointestinal symptoms and myelosuppression. Future large-scale, high-quality, placebo-controlled, double-blind trials are needed. © 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins. Source

Discover hidden collaborations